Skip to main content

Table 1 Effect of Doxorubicin (DOX) and different treatments of AHE on Liver Function tests (LFTs)

From: Effect of Acacia hydaspica R. Parker extract on lipid peroxidation, antioxidant status, liver function test and histopathology in doxorubicin treated rats

Treatment (mg/kg) ALT (U/l) AST (U/l) ALP (U/l) LDH (U/l) Total bilirubin (TB mg/dl) Direct bilirubin (DB mg/dl)
Control 44.63 ± 0.491b 72.83 ± 0.120b 120.7 ± 0.333b 48.62 ± 0.232 b 0.92 ± 0.015b 0.303 ± 0.037b
DOX 139.80 ± 0.336a 191.0 ± 0.577a 355.8 ± 0.120a 171.10 ± 0.358 a 1.84 ± 0.016a 0.546 ± 0.017a
AHE alone 44.57 ± 0.233b 72.63 ± 0.186b 120.7 ± 0.208b 48.57 ± 0.203 b 0.917 ± 0.013b 0.300 ± 0.036b
DOX + AHE (200) 79.62 ± 0.523a, b, d 135.9 ± 0.133a, b, d 211.2 ± 0.441a, b, d 98.97 ± 0.548a, b, d 1.45 ± 0.023a, b, d 0.443 ± 0.009a*
DOX + AHE (400) 47.27 ± 0.318a**, b, c 76.83 ± 0.167a, b, c 134.8 ± 0.338a, b, c 60.37 ± 0.578a, b, c 1.193 ± 0.012a, b, c 0.348 ± 0.024b**
DOX + Sily 46.47 ± 0.176a*, b 76.13 ± 0.133a, b 133.1 ± 0.591a, b 58.67 ± 0.333 a, b 1.18 ± 0.015a, b 0.345 ± 0.020b**
  1. Values expressed as mean ± SEM. a Significance at p < 0.0001 Vs. control group, b Significance at p < 0.0001 Vs. Doxorubicin (DOX) group, c Significance at p < 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. d Significance at p < 0.0001 of AHE co-treatment groups Vs DOX + Sily group. *, ** Significant difference at p < 0.05 and p < 0.001 respectively. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey’s multiple comparison tests). Sily-Silymarin